Can-Fite BioPharma Ltd. (CANF)
USD 1.53
(9.44%)
USD 1.53
(9.44%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.74 Million USD | -22.14% |
| 2022 | 4.81 Million USD | -18.05% |
| 2021 | 5.87 Million USD | 70.22% |
| 2020 | 3.44 Million USD | -39.83% |
| 2019 | 5.73 Million USD | 16.1% |
| 2018 | 4.93 Million USD | 3.32% |
| 2017 | 4.77 Million USD | -24.07% |
| 2016 | 6.29 Million USD | -12.06% |
| 2015 | 7.15 Million USD | 114.89% |
| 2014 | 3.33 Million USD | 52.99% |
| 2013 | 2.17 Million USD | -7.11% |
| 2012 | 2.34 Million USD | 45.41% |
| 2011 | 1.61 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.44 Million USD | 0.0% |
| 2024 Q1 | 3.44 Million USD | -8.09% |
| 2023 Q4 | 3.74 Million USD | -4.78% |
| 2023 FY | 3.74 Million USD | -22.14% |
| 2023 Q1 | 4.99 Million USD | 3.85% |
| 2023 Q2 | 4.15 Million USD | -16.77% |
| 2023 Q3 | 3.93 Million USD | -5.39% |
| 2022 Q1 | 5.82 Million USD | -0.82% |
| 2022 Q4 | 4.81 Million USD | -8.85% |
| 2022 Q3 | 5.27 Million USD | 8.74% |
| 2022 FY | 4.81 Million USD | -18.05% |
| 2022 Q2 | 4.85 Million USD | -16.64% |
| 2021 Q1 | 5.66 Million USD | 64.22% |
| 2021 Q4 | 5.87 Million USD | 10.67% |
| 2021 Q3 | 5.3 Million USD | -7.34% |
| 2021 Q2 | 5.72 Million USD | 1.08% |
| 2021 FY | 5.87 Million USD | 70.22% |
| 2020 Q1 | 4.77 Million USD | -34.52% |
| 2020 Q2 | 3.64 Million USD | -23.75% |
| 2020 FY | 3.44 Million USD | -39.83% |
| 2020 Q3 | 3.78 Million USD | 3.87% |
| 2020 Q4 | 3.44 Million USD | -8.88% |
| 2019 Q1 | 4.24 Million USD | -14.04% |
| 2019 Q4 | 7.29 Million USD | 55.44% |
| 2019 Q2 | 5.22 Million USD | 23.14% |
| 2019 Q3 | 4.69 Million USD | -10.16% |
| 2019 FY | 5.73 Million USD | 16.1% |
| 2018 FY | 4.93 Million USD | 3.32% |
| 2018 Q4 | 4.93 Million USD | 11.24% |
| 2018 Q3 | 4.43 Million USD | -0.8% |
| 2018 Q2 | 4.47 Million USD | -11.34% |
| 2018 Q1 | 5.04 Million USD | 5.6% |
| 2017 Q3 | 5.29 Million USD | -14.96% |
| 2017 Q2 | 6.23 Million USD | -2.91% |
| 2017 Q1 | 6.41 Million USD | 1.99% |
| 2017 FY | 4.77 Million USD | -24.07% |
| 2017 Q4 | 4.77 Million USD | -9.83% |
| 2016 FY | 6.29 Million USD | -12.06% |
| 2016 Q2 | 6 Million USD | -15.33% |
| 2016 Q4 | 6.29 Million USD | 6.58% |
| 2016 Q1 | 7.09 Million USD | -0.87% |
| 2016 Q3 | 5.9 Million USD | -1.7% |
| 2015 Q3 | 8.11 Million USD | 129.02% |
| 2015 Q2 | 3.54 Million USD | -2.84% |
| 2015 Q1 | 3.64 Million USD | 9.56% |
| 2015 Q4 | 7.15 Million USD | -11.86% |
| 2015 FY | 7.15 Million USD | 114.89% |
| 2014 Q1 | 2.47 Million USD | 13.51% |
| 2014 Q4 | 3.33 Million USD | 77.61% |
| 2014 Q3 | 1.87 Million USD | 5.15% |
| 2014 FY | 3.33 Million USD | 52.99% |
| 2014 Q2 | 1.78 Million USD | -27.83% |
| 2013 Q2 | 3.34 Million USD | -12.2% |
| 2013 Q3 | 1.46 Million USD | -56.11% |
| 2013 Q1 | 3.8 Million USD | 62.37% |
| 2013 FY | 2.17 Million USD | -7.11% |
| 2013 Q4 | 2.17 Million USD | 48.46% |
| 2012 Q1 | 1.74 Million USD | 8.48% |
| 2012 Q3 | 1.48 Million USD | 10.88% |
| 2012 Q4 | 2.34 Million USD | 57.45% |
| 2012 Q2 | 1.34 Million USD | -23.22% |
| 2012 FY | 2.34 Million USD | 45.41% |
| 2011 FY | 1.61 Million USD | 0.0% |
| 2011 Q4 | 1.61 Million USD | 44.19% |
| 2011 Q3 | 1.11 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | 59.047% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -57.66% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 97.363% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 91.688% |
| Azitra, Inc. | 2.2 Million USD | -70.092% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | 42.73% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | 79.478% |
| CEL-SCI Corporation | 17.31 Million USD | 78.364% |
| iBio, Inc. | 7.41 Million USD | 49.447% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | 90.394% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | 47.16% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 91.915% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 70.068% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | 34.51% |
| NanoViricides, Inc. | 1.35 Million USD | -175.689% |
| Oragenics, Inc. | 1.79 Million USD | -108.322% |
| BiomX Inc. | 55.07 Million USD | 93.198% |
| BiomX Inc. | 55.07 Million USD | 93.198% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 92.635% |
| Palatin Technologies, Inc. | 10.85 Million USD | 65.487% |
| Scorpius Holdings, Inc. | 22.74 Million USD | 83.529% |
| Theriva Biologics, Inc. | 20.51 Million USD | 81.739% |